In Brief: Lifecore Biomedical/Storz Ophthalmics
This article was originally published in The Gray Sheet
Executive Summary
Lifecore Biomedical/Storz Ophthalmics: Companies ink deal under which Lifecore will develop the manufacturing process for American Home Products subsidiary Storz' new "injectable gel implant technology," which is intended to be used in the treatment of myopia. The companies expect to enter a commercial supply relationship if Storz gains approval of the product. With the technology, "a small amount of a stable polyethylene oxide gel is injected into the peripheral region of the cornea, between the inner and outer layers, changing the corneal curvature," a Lifecore release states. Lifecore claims that the implantable gel technology could offer advantages over current techniques such as photorefractive keratectomy. The cost of the gel product is expected to be competitive with current corrective techniques...